Amendment 3 to the Solicitation - Operate, Maintain and Improve the existing Proteomic Data Commons (PDC)

This Special Notice has been released to notify Offerors of an Amendment to Solicitation S23-072. This Special Notice is NOT to provide notice of a new Solicitation, but rather to update Offerors with Answers to Questions received regarding Solicitation S23-072. A Special Notice for the Leidos Biomedical Research “Request for Proposal (RFP) S23-072 to Maintain, Operate, and Improve the PDC” was previously posted to SAM.gov on May 16, 2023. ( https://sam.gov/opp/cda50ba1ffb945e3b7505229a825b92f/view#general ) . Leidos Biomedical Research, Inc. (Leidos Biomed), a subsidiary of Leidos Corporation, a Delaware corporation with offices in Frederick, MD is the Operations and Technical Support (OTS) contractor for the National Cancer Institute at Frederick. The effort to be performed will be part of Leidos Biomed’s Prime Contract 75N91019D00024 that has been issued by the National Cancer Institute, National Institutes of Health, Frederick, MD. Description of Work - National Cancer Institute’s Proteomic Data Commons (PDC) is the largest public repository of comprehensive tumor proteomic datasets. It’s a cloud-based resource that collects, harmonizes, and hosts mass spectrometry-based proteomic data along with corresponding metadata across a variety of tumor types from programs including Clinical Proteomic Tumor Analysis Consortium (CPTAC), International Cancer Proteogenome Consortium (ICPC) and the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network. The PDC data portal is open access and provides end users with appropriate compute capacity to support large-scale analytical capabilities. PDC also maps datasets, when available, to corresponding genomic and/or imaging data within the NCI Cancer Research Data Commons (CRDC).